More MS news articles for Nov 2001

Treatment of multiple sclerosis patients with interferon-beta primes monocyte-derived macrophages for apoptotic cell death

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11698494&dopt=Abstract

J Leukoc Biol 2001 Nov;70(5):745-8
Van Weyenbergh J, Wietzerbin J, Rouillard D, Barral-Netto M, Liblau R.
U365 INSERM, Section de Recherche, Institut Curie. U546 INSERM, Hopital La Pitie-Salpetriere, Paris, France. Goncalo Moniz Research Center, Oswaldo Cruz Foundation, Salvador-Bahia, Brazil.

Although interferon (IFN)-beta has shown a significant clinical benefit in multiple sclerosis (MS), its mechanism of action remains unclear.

We found that IFN-beta treatment of patients with MS resulted in a significant increase in apoptotic cell death (measured by annexin V staining and nuclear fragmentation) of monocyte-derived macrophages, as compared with cells derived from patients before treatment.

Stimulation of the cells with IFN-beta in vitro resulted in an even further increase of annexin V binding, as well as increased Fas (CD 95, APO-1) expression.

However, no increased Fas expression, apoptotic monocytes, or monocytopenia were observed upon in vivo treatment.

This indicates that IFN-beta does not deliver a death signal to monocytes but rather primes for subsequent macrophage apoptosis upon activation or differentiation.
 

PMID: 11698494 [PubMed - in process]